The explains alex rodriguez bank released texas rangers badge fells in a summary of the report on June 19[ID:nPEK107283] (Reporting by Zhou Xin, Aileen Wang and Alan Wheatley; Editingby Chris Lewis) Currencies. This is PR NEWSWIRE -- transmitting news releases, advisories andother information to the news media around the United States since1954.If you have questions regarding your PRN teleprinter, your PRN computerservice, or if you wish to arrange to receive PR NEWSWIRE in your editorialcomputer system, please call: PRN Media Services at 201-946-5589 (Outside New York State:800-832-5522, ext. 5589)For repeats or other information, please call the PRN editorial desk at800-776-8090, or your nearest PR Newswire bureau:Atlanta404-231-1814 Nashville615-783-1632Austin 512-328-1006 Orange County714-251-6993Boston 617-482-5355 Philadelphia 800-523-4424Charlotte704-338-9366 Phoenix602-655-8892Chicago888-776-6551 Pittsburgh 412-232-3050Cleveland216-566-7777 Salt Lake City 801-350-9402Dallas 888-776-3971 San Diego619-456-5740Denver 303-291-0550 San Francisco415-543-7800Detroit248-352-5200 San Jose 408-295-3600Houston800-776-8390 Seattle206-624-2414Los Angeles213-626-5500 Tampa813-228-8810Miami305-461-8666 Washington, D.C. BRUSSELS, BELGIUM, Jun 26 (MARKET WIRE) -- Press Release, regulated information - UCB announced today that theCommittee for Medicinal Products for Human Use (CHMP) of the EuropeanMedicines Agency (EMEA) has issued a positive opinion recommending thatthe European Commission grants a marketing authorisation for Cimzia(R)(certolizumab pegol), in combination with methotrexate (MTX), for thetreatment of moderate to severe active rheumatoid arthritis in adultpatients when the response to disease-modifying anti-rheumatic drugs(DMARDs) including MTX, has been inadequate. In these patients, Cimzia(R)can be given as monotherapy in case of intolerance to MTX or whencontinued treatment with MTX is inappropriate.
Cimzia(R) has been shownto reduce the rate of progression of joint damage as measured by X-rayand to improve physical function, when given in combination with MTX.The recommendation has been granted for Cimzia(R) to be administered as asubcutaneous injection using the pre-filled syringe."The CHMP positive opinion is a significant milestone for UCB, butespecially for people suffering from rheumatoid arthritis," said RochDoliveux, Chief Executive Officer of UCB baseball tickets . A pooled analysis of the safety data showed a lowincidence of injection site pain (1.5%) and a low level ofdiscontinuations due to adverse events (5%) texas rangers badges . Cimzia(R) demonstrated afavorable risk-benefit profile in patients with at least up to two yearsof drug exposure.On 14 May, the U.S walker texas rangers . Over the pastdecade, TNF-alpha has emerged as a major target of basic research andclinical investigation texas rangers badge . This cytokine plays a key role in mediatingpathological inflammation, and excess TNF-alpha production has beendirectly implicated in a wide variety of diseases.The U.S.
Food and Drug Administration (FDA) has approved Cimzia(R) forreducing signs and symptoms of Crohn's disease and maintaining clinicalresponse in adult patients with moderate to severe active disease whohave had an inadequate response to conventional therapy and for thetreatment of adults with moderate to severely active rheumatoid arthritis.Cimzia(R) was approved in Switzerland in September 2007 for induction ofa clinical response and for the maintenance of a clinical response and aremission in patients with active Crohn's disease who have not respondedadequately to conventional treatment michael young autograph . UCB is also developing Cimzia(R) inother autoimmune disease indications texas rangers badges . Cimzia(R) is a registered trademarkof UCB PHARMA S.A.Reported serious adverse reactions of Cimzia(R) were infections(including tuberculosis and histoplasmosis) and malignancies includinglymphoma walker texas rangers . The most commonly occurring adverse events were upperrespiratory tract infections, rash and urinary tract infections . A pooledanalysis of the safety data show there was a low incidence of injectionsite pain (1.5%) and a low level of discontinuations due to adverseevents (5%).About UCBUCB, Brussels, Belgium () is a biopharmaceutical companydedicated to the research, development and commercialisation ofinnovative medicines with a focus on the fields of central nervous systemand immunology disorders. Employing approximately 10 000 people in over40 countries, UCB generated revenue of EUR 3.6 billion in 2008.
Comments are closed.